Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
39.38
+1.27 (3.33%)
At close: Dec 5, 2025, 4:00 PM EST
39.98
+0.60 (1.52%)
After-hours: Dec 5, 2025, 6:51 PM EST
Zenas BioPharma Employees
Zenas BioPharma had 130 employees as of December 31, 2024.
Employees
130
Change
n/a
Growth
n/a
Revenue / Employee
$115,385
Profits / Employee
-$1,460,762
Market Cap
2.11B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 130 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ZBIO News
- 24 days ago - Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 25 days ago - Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 5 weeks ago - Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis - GlobeNewsWire
- 7 weeks ago - Chairman and CEO of Zenas BioPharma (ZBIO) Buys 36,928 Shares for $769,948 - The Motley Fool
- 2 months ago - Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal - Seeking Alpha
- 2 months ago - Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug - Reuters
- 2 months ago - Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis - GlobeNewsWire
- 3 months ago - Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million - GlobeNewsWire